Altimmune (ALT) Set to Announce Quarterly Earnings on Wednesday

Altimmune (NASDAQ:ALT - Get Free Report) will be announcing its earnings results before the market opens on Wednesday, March 27th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

Altimmune Price Performance

Altimmune stock traded down $0.23 during trading hours on Thursday, hitting $9.11. The company had a trading volume of 2,746,744 shares, compared to its average volume of 6,133,274. The firm has a 50-day moving average of $10.18 and a 200 day moving average of $6.47. The firm has a market cap of $489.48 million, a PE ratio of -5.99 and a beta of 0.08. Altimmune has a one year low of $2.09 and a one year high of $14.84.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ALT shares. B. Riley restated a "buy" rating and issued a $20.00 price target on shares of Altimmune in a research note on Tuesday, February 13th. The Goldman Sachs Group began coverage on Altimmune in a research note on Wednesday, January 24th. They issued a "neutral" rating and a $13.00 price target for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Altimmune in a research report on Friday, December 1st.

Hedge Funds Weigh In On Altimmune

Several hedge funds have recently modified their holdings of ALT. State Street Corp lifted its position in shares of Altimmune by 2,407.5% during the 3rd quarter. State Street Corp now owns 3,398,856 shares of the company's stock worth $43,403,000 after buying an additional 3,263,310 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Altimmune by 162.9% in the 2nd quarter. BlackRock Inc. now owns 3,664,274 shares of the company's stock worth $12,935,000 after purchasing an additional 2,270,219 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Altimmune in the 4th quarter worth approximately $14,023,000. Balyasny Asset Management LLC raised its holdings in shares of Altimmune by 402.6% in the 3rd quarter. Balyasny Asset Management LLC now owns 1,037,662 shares of the company's stock worth $13,251,000 after purchasing an additional 831,193 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Altimmune by 101.1% in the 2nd quarter. Geode Capital Management LLC now owns 969,861 shares of the company's stock worth $3,424,000 after purchasing an additional 487,500 shares during the period. Institutional investors own 66.99% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.